AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6511088
Drug: Erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin stearate (500 mg tablets)
Trial: 6511088
Drug: Erythromycin base
RxNorm normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin base (500 mg enteric-coated pellets)
Trial: 29155123
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro low mixture (LM)
Trial: 26019334
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg) administered intravenously
Trial: 23216417
Drug: Alcohol +
RxNorm normalized name: Benzyl alcohol + eucalyptus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol + diet beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg diet Squirt)
Trial: 23216417
Drug: Alcohol +
RxNorm normalized name: Benzyl alcohol + eucalyptus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol + regular beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg Squirt)
Trial: 12690273
Drug: Pleconaril, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pleconaril, 5 mg/kg/dose orally three times a day for 7 days
Trial: 8960577
Drug: Non-aspirin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin treatment
Trial: 30319652
Drug: QBECO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBECO treatment
Trial: 25706882
Drug: Ozanezumab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanezumab, a humanised IgG monoclonal antibody against Nogo‐A protein, administered intravenously in a first‐in‐human study.
Trial: 25706882
Drug: Ozanezumab, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozanezumab, administered intravenously, with one or two doses.
Trial: 22738802
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg/day
Trial: 22738802
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg/day
Trial: 21560631
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily + UDCA 10 mg/kg daily
Trial: 9663727
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily
Trial: 3932054
Drug: Misoprostol 25
RxNorm normalized name: Misoprostol 25 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 25 micrograms q.i.d. with aspirin 650 mg q.i.d.
Trial: 26590023
Drug: Intensive psychotherapy
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive psychotherapy plus pharmacotherapy
Trial: 26590023
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (three-session psycho-educational intervention) plus pharmacotherapy
Trial: 26590023
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care plus pharmacotherapy
Trial: 24226057
Drug: Earlier ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Earlier ART (within 2 weeks after TB treatment initiation)
Trial: 24226057
Drug: Later ART
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later ART (8-12 weeks after TB treatment)
Trial: 22576712
Drug: Synbiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic therapy (Lactobacillus, Bifidobacterium, and galactooligosaccharides) for 8 weeks
Trial: 7590485
Drug: Intraperitoneal interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal interferon-alpha 2b (5-30 x 10(6) units) administered on Day 1 (+/- Day 8)
Trial: 7590485
Drug: Intravenous cis-platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cis-platinum (75 mg/m2) plus cyclophosphamide (750 mg/m2) administered on Day 2
Trial: 3918969
Drug: Conventional dose/fraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose/fraction (180‐200 cGy) X 5 days/week (Group A)
Trial: 20576763
Drug: 2% topical
RxNorm normalized name: A/T/S 2% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% topical ciclosporin A
Trial: 15663445
Drug: acid etching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acid etching and application of a bonding agent
Trial: 12244290
Drug: Midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.3 mg/kg and Ketamine 2 mg/kg (MK2)
Trial: 12244290
Drug: Midazolam 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.3 mg/kg and Ketamine 1 mg/kg (MK1)
Trial: 12244290
Drug: Midazolam 0.5
RxNorm normalized name: midazolam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.5 mg/kg (Control group M)
Trial: 10397661
Drug: 5% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acyclovir cream (Zovirax cream)
Trial: 2271366
Drug: Dilevalol (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol (100-400 mg daily)
Trial: 389818
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g sulphamethizole twice daily
Trial: 389818
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg trimethoprim twice daily
Trial: 389818
Drug: 410 mg
RxNorm normalized name: aspirin 410 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 410 mg sulphadiazine plus 90 mg trimethoprim twice daily
Trial: 389818
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg trimethoprim alone
Trial: 389818
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g sulphamethizole
Trial: 389818
Drug: 410 mg
RxNorm normalized name: aspirin 410 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 410 mg sulphadiazine plus 90 mg trimethoprim
Trial: 25504811
Drug: Biologic disease‐modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic disease‐modifying antirheumatic drugs (DMARDs)
Trial: 15055997
Drug: Sitaxsentan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan 100 mg once daily
Trial: 17335962
Drug: Active magnetic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active magnetic stimulation (Neocontrol), 20 treatments of 20 minutes each over six weeks.
Trial: 17335962
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (identical looking/sounding device with deflector plate), 20 treatments of 20 minutes each over six weeks.
Trial: 9308642
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood components (not screened for CMV antibody)
Trial: 7959579
Drug: Chemotherapy (cisplatinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatinum and 5-fluorouracil) and radiation followed by resection
Trial: 3311054
Drug: bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (200 mg t.i.d.)
Trial: 3311054
Drug: colestyramine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colestyramine (4 g t.i.d.)
Trial: 31559844
Drug: Fascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial therapy (1 session per week for 3 weeks)
Trial: 25629321
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone 8 mg (DexIV)
Trial: 25629321
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 8 mg (DexP)
Trial: 25629321
Drug: Control (30-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (30-mL bupivacaine 0.5% alone)
Trial: 23566943
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (7000 IU daily for 26 weeks)
Trial: 20931100
Drug: LOS 150
RxNorm normalized name: Rea-Lo 150 MG/ML Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS 150 mg/HCTZ 25 mg
Trial: 20931100
Drug: LOS 150
RxNorm normalized name: Rea-Lo 150 MG/ML Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOS 150 mg/HCTZ 37.5 mg
Trial: 18222735
Drug: Goshuyuto extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goshuyuto extract for 1 month, followed by 3 months of goshuyuto in the treatment group.
Trial: 15973834
Drug: CSEB applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSEB applied without any cavity preparation
Trial: 26901353
Drug: 840 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 840 mg/day DHA
Trial: 19148407
Drug: 4% titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% titanium tetrafluoride solution (TiF4)
Trial: 9805071
Drug: Heberbiovac-HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heberbiovac-HB vaccine at 10 g
Trial: 9805071
Drug: Heberbiovac-HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heberbiovac-HB vaccine at 5 g
Trial: 9805071
Drug: Heberbiovac-HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heberbiovac-HB vaccine at 2.5 g
Trial: 2032492
Drug: Autologous LAK
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous LAK cell reinfusion treatment for 6 weeks
Trial: 2032492
Drug: 10% glucose
RxNorm normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glucose solution intravenous drip for 6 weeks
Trial: 7226903
Drug: High-dose theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose theophylline
Trial: 7226903
Drug: Fenoterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (10 mg)
Trial: 7226903
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (130 mg)
Trial: 7226903
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (130 mg) + fenoterol (5 mg)
Trial: 19081652
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Paclitaxel 200 mg/m2 and carboplatin AUC6 with accelerated radiotherapy 1.7 Gy BID to 64.6 Gy in 4.5 weeks.
Trial: 19081652
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy 2 Gy to 60 Gy in 6 weeks.
Trial: 19081652
Drug: Arm C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm C: Weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy.
Trial: 19081652
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group not specified as there are three treatment arms.
Trial: 17868210
Drug: Boiled extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boiled extract of Nigella sativa (15 mL/kg of 0.1 g%)
Trial: 15115259
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of vitamin B6 daily and one monthly injection of 200 microg vitamin B12, plus 15 mg folic acid daily (group A)
Trial: 15115259
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of vitamin B6 daily and one monthly injection of 1,000 microg vitamin B12, plus 15 mg folic acid daily (group B)
Trial: 7483616
Drug: Proajmaline (neogilurytmal)
RxNorm normalized name: prajmaline
DrugBank: Prajmaline (DB13555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proajmaline (neogilurytmal) 3 x 20 mg
Trial: 7483616
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (neogilurytmal 2 x 20 mg and magnesium 2 x 0.6)
Trial: 3190993
Drug: Allopurinol 50
RxNorm normalized name: allopurinol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 50 mg daily
Trial: 6847424
Drug: Allopurinol 100
RxNorm normalized name: allopurinol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 100 mg daily
Trial: 3190993
Drug: Allopurinol 600
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 600 mg daily
Trial: 3190993
Drug: Allopurinol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (various doses)
Trial: 123426
Drug: Leukocytic interferon
RxNorm normalized name: interferon alfa-3n,human leukocyte derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytic interferon with metacyl (0.25 ml once a day)
Trial: 31076203
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg of nemiralisib via Ellipta dry powder inhaler
Trial: 31076203
Drug: 750 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 μg of nemiralisib via Ellipta dry powder inhaler
Trial: 26964165
Drug: Tamsulosin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.2 mg, twice a day for 1 month)
Trial: 22924409
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg once daily for 5 days (n = 48)
Trial: 22924409
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg administered 24 h post-warfarin
Trial: 18294998
Drug: Idraparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idraparinux (2.5 mg weekly)
Trial: 18294998
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (adjusted-dose, target INR 2-3)
Trial: 12641543
Drug: Topical 5‐ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5‐ASA 2 g and 80 mM L‐1 sodium‐butyrate bid (Group A)
Trial: 12641543
Drug: 5‐ASA 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA 2 g and 80 mL saline bid (Group B)
Trial: 10637255
Drug: ACE chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE chemotherapy every 2 weeks with G-CSF support
Trial: 10637255
Drug: ACE chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE chemotherapy every 3 weeks (control group)
Trial: 7908879
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no H2 receptor antagonist)
Trial: 16417414
Drug: Other sex
RxNorm normalized name: Other sex hormones and modulators of the genital system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other sex steroid levels (estrone, total estradiol, total testosterone)
Trial: 12716250
Drug: THC (delta‐9‐tetrahydrocannabinol)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC (delta‐9‐tetrahydrocannabinol) up to 10 mg/day for 6 weeks
Trial: 10793162
Drug: Ventilation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilation with lower tidal volumes (initial tidal volume of 6 ml per kilogram of predicted body weight, plateau pressure of 30 cm of water or less)
Trial: 10793162
Drug: Traditional ventilation
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional ventilation treatment (initial tidal volume of 12 ml per kilogram of predicted body weight, plateau pressure of 50 cm of water or less)
Trial: 9489309
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg i.v.) administered immediately after induction and for postoperative analgesia beginning at skin closure
Trial: 9489309
Drug: No ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ketorolac administered before the operation, postoperative treatment same as intervention group
Trial: 22290668
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg caffeine in de-caffeinated coffee
Trial: 3899404
Drug: Dipyridamole-aspirin
RxNorm normalized name: aspirin / dipyridamole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole-aspirin
Trial: 3899404
Drug: Pentoxifylline-aspirin
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline-aspirin
Trial: 31465307
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) performed twice daily for 4 weeks starting 3 days after surgery
Trial: 29504328
Drug: Dexamethasone 8mg
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 8mg intravenously preoperatively and second dose 4 hours postoperatively
Trial: 26827617
Drug: Feedback-incentive (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback-incentive (monthly letter with social norm feedback plus small financial incentive for increasing green purchases)
Trial: 26827617
Drug: Feedback-only (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feedback-only (monthly letter with social norm feedback about healthy food purchases)
Trial: 22693239
Drug: CHO‐PRO solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐PRO solution (1.2 g CHO/kg body mass and 0.4 g PRO/kg body mass)
Trial: 22693239
Drug: CHO‐PRO solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐PRO solution
Trial: 22693239
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (CON)
Trial: 18375410
Drug: Diane(35) Diario
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane(35) Diario (35 mg ethinyl-estradiol plus 2 mg cyproterone acetate)
Trial: 11672911
Drug: BCG vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccination before last DTP vaccine
Trial: 11672911
Drug: Antimalarials within
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarials within last week
Trial: 7961349
Drug: Therapy received
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy received by 65% of abused children for an average of 9 months.
Trial: 3298694
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin therapy with quarterly maintenance instillations
Trial: 3298694
Drug: Bacillus Calmette-Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guerin therapy without maintenance instillations
Trial: 3298694
Drug: Maintenance bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance bacillus Calmette-Guerin therapy
Trial: 21167334
Drug: Platelet function
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet function monitoring with dose adjustment in suboptimal responders
Trial: 21167334
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of dual antiplatelet therapy beyond 1 year
Trial: 21167334
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care without monitoring and without dose adjustment
Trial: 9039228
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus adjuvant chemotherapy (cyclophosphamide, vincristine and prednisone)
Trial: 1357681
Drug: CGP 361
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 361 A (beta-blocking drug)
Trial: 1357681
Drug: Flupenthixol (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol (low-dose neuroleptic)
Trial: 29934046
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (0.5, 1, and 2 g daily)
Trial: 27239991
Drug: Cytoflavin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (2 tabs. 2 times a day for 25 days) + cognitive therapy
Trial: 12860497
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by Galantamine 24 mg/d
Trial: 2004540
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation (1.67 mg/ml)
Trial: 2004540
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tablet (2 x 200 mg)
Trial: 2004540
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tablet
Trial: 6439360
Drug: Theophylline (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (200, 400, 600, and 800 mg)
Trial: 29454514
Drug: Intermittent linsitinib
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent linsitinib (600mg once daily on Days 1-3 per week) with paclitaxel (80mg/m2 on Days 1, 8, and 15)